Literature DB >> 31848928

Diagnosis of cardiac sarcoidosis: an era of paradigm shift.

Apurva Sharma1, David R Okada1, Harout Yacoub2, Jonathan Chrispin1, Sabahat Bokhari3.   

Abstract

Cardiac sarcoidosis is a granulomatous disease that may affect any organ, including the heart. Diagnosis of cardiac sarcoidosis is challenging, given the varied and non-specific clinical presentation and limited sensitivity and specificity of available diagnostic tests. With the growing interest and developments in imaging techniques, cardiac magnetic resonance imaging (CMR) and positron emission tomography (PET) have emerged as important tools in the diagnostic evaluation of patients with suspected cardiac sarcoidosis. These modalities have been given increasing emphasis in successive published diagnostic guidelines for CS. This review will provide an update on the recent paradigm shift in diagnostic guidelines for cardiac sarcoidosis, with a focus on the advanced cardiac imaging modalities and their developed role in clinical practice.

Entities:  

Keywords:  Cardiac magnetic resonance imaging; Cardiac sarcoidosis; Diagnostic guidelines; Echocardiography; Fluorodeoxy-glucose positron emission tomography

Year:  2019        PMID: 31848928     DOI: 10.1007/s12149-019-01431-z

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  3 in total

Review 1.  Cardiac MRI-Update 2020.

Authors:  Anke Busse; Rengarajan Rajagopal; Seyrani Yücel; Ebba Beller; Alper Öner; Felix Streckenbach; Daniel Cantré; Hüseyin Ince; Marc-André Weber; Felix G Meinel
Journal:  Radiologe       Date:  2020-11       Impact factor: 0.635

2.  Conduction disorders as the first hallmark of isolated cardiac sarcoidosis in a highly active individual: a case report.

Authors:  Silvia Muccioli; Stefano Albani; Barbara Mabritto; Giuseppe Musumeci
Journal:  Eur Heart J Case Rep       Date:  2021-10-12

Review 3.  Heart failure and cardiac imaging: Choosing wisely in the era of multimodality imaging.

Authors:  Frank Flachskampf; Tomasz Baron
Journal:  Anatol J Cardiol       Date:  2020-03       Impact factor: 1.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.